Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Risk of skin cancer in patients with vitiligo in Denmark: A nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Adverse reactions to tattoos in the general population of Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Risk of skin cancer in HIV-infected patients: a Danish nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Danish guidelines for management of non-APC-associated hereditary polyposis syndromes

    Research output: Contribution to journalReviewResearchpeer-review

  2. Selection criteria for assembling a pediatric cancer predisposition syndrome gene panel

    Research output: Contribution to journalJournal articleResearchpeer-review

  • GenoMEL Study Group
View graph of relations

Background: Although rare in the general population, highly penetrant germline mutations in CDKN2A are responsible for 5%-40% of melanoma cases reported in melanoma-prone families. We sought to determine whether MELPREDICT was generalizable to a global series of families with melanoma and whether performance improvements can be achieved. Methods: In total, 2116 familial melanoma cases were ascertained by the international GenoMEL Consortium. We recapitulated the MELPREDICT model within our data (GenoMELPREDICT) to assess performance improvements by adding phenotypic risk factors and history of pancreatic cancer. We report areas under the curve (AUC) with 95% confidence intervals (CIs) along with net reclassification indices (NRIs) as performance metrics. Results: MELPREDICT performed well (AUC 0.752, 95% CI 0.730-0.775), and GenoMELPREDICT performance was similar (AUC 0.748, 95% CI 0.726-0.771). Adding a reported history of pancreatic cancer yielded discriminatory improvement (P < .0001) in GenoMELPREDICT (AUC 0.772, 95% CI 0.750-0.793, NRI 0.40). Including phenotypic risk factors did not improve performance. Conclusion: The MELPREDICT model functioned well in a global data set of familial melanoma cases. Adding pancreatic cancer history improved model prediction. GenoMELPREDICT is a simple tool for predicting CDKN2A mutational status among melanoma patients from melanoma-prone families and can aid in directing these patients to receive genetic testing or cancer risk counseling.

Original languageEnglish
JournalJournal of the American Academy of Dermatology
Volume81
Issue number2
Pages (from-to)386-394
Number of pages9
ISSN0190-9622
DOIs
Publication statusPublished - 1 Aug 2019

    Research areas

  • CDKN2A, familial melanoma, GenoMEL, GenoMELPREDICT, mutation prediction

ID: 58278756